NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the
efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a first-line
monotherapeutic agent in patients with lung adenocarcinoma harboring EGFR mutation.